Association of DAOA polymorphisms with schizophrenia and clinical symptoms or therapeutic effects

Neuroscience Letters

Volumn 416, Issue 1, 2007, Pages 96-100

  Yue, Weihua ^a   Kang, Guolian ^b,c   Zhang, Yanbo ^a   Qu, Mei ^a   Tang, Fulei ^a   Han, Yonghua ^a   Ruan, Yan ^a   Lu, Tianlan ^a   Zhang, Jifeng ^b   Zhang, Dai ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b CHINESE ACADEMY OF SCIENCES   (China)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Association study; Clinical symptom; DAOA; Schizophrenia; Therapeutic effect

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DEXTRO AMINO ACID OXIDASE; OLANZAPINE; RISPERIDONE; SULPIRIDE;

ADULT; ALLELE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DEXTRO AMINO ACID OXIDASE ACTIVATOR GENE; DNA POLYMORPHISM; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CASE-CONTROL STUDIES; DRUG RESISTANCE; FAMILY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCHIZOPHRENIA;

EID: 33947251327     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2007.01.056     Document Type: Article

References (28)

1. Badner J.A., and Gershon E.S. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol. Psychiatry 7 (2002) 405-411
2. Bishop J.R., Ellingrod V.L., Moline J., and Miller D. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr. Res. 77 (2005) 253-260
3. Blouin J.L., Dombroski B.A., Nath S.K., Lasseter V.K., Wolyniec P.S., Nestadt G., Thornquist M., Ullrich G., McGrath J., Kasch L., Lamacz M., Thomas M.G., Gehrig C., Radhakrishna U., Snyder S.E., Balk K.G., Neufeld K., Swartz K.L., DeMarchi N., Papadimitriou G.N., Dikeos D., Stefanis C.N., Chakravarti A., Childs B., Housman D.E., Kazazian H.H., Antonarakis S., and Pulver A.E. Schizophrenia susceptibility loci on chromosomes 13q32 and 8p21. Nat. Genet. 20 (1998) 70-73
4. Brzustowicz L.M., Honer W.G., Chow E.W., Little D., Hogan J., Hodgkinson K., and Bassett A.S. Linkage of familial schizophrenia to chromosome 13q32. Am. J. Hum. Genet. 65 (1999) 1096-1103
5. Camp N.J., Neuhausen S.L., Tiobech J., Polloi A., Coon H., and Myles-Worsley M. Genomewide multipoint linkage analysis of seven extended Palauan pedigrees with schizophrenia, by a Markov-chain Monte Carlo method. Am. J. Hum. Genet. 69 (2001) 1278-1289
6. Cardno A.G., Holmans P.A., Rees M.I., Jones L.A., McCarthy G.M., Hamshere M.L., Williams N.M., Norton N., Williams H.J., Fenton I., Cardno A.G., Holmans P.A., Rees M.I., Jones L.A., McCarthy G.M., Hamshere M.L., Williams N.M., Norton N., Williams H.J., Fenton I., Murphy K.C., Sanders R.D., Gray M.Y., O'Donovan M.C., McGuffin P., and Owen M.J. A genomewide linkage study of age at onset in schizophrenia. Am. J. Med. Genet. 105 (2001) 439-445
7. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., Bougueleret L., Barry C., Tanaka H., La Rosa P., Puech A., Tahri N., Cohen-Akenine A., Delabrosse S., Lissarrague S., Picard F.P., Maurice K., Essioux L., Millasseau P., Grel P., Debailleul V., Simon A.M., Caterina D., Dufaure I., Malekzadeh K., Belova M., Luan J.J., Bouillot M., Sambucy J.L., Primas G., Saumier M., Boubkiri N., Martin-Saumier S., Nasroune M., Peixoto H., Delaye A., Pinchot V., Bastucci M., Guillou S., Chevillon M., Sainz-Fuertes R., Meguenni S., Aurich-Costa J., Cherif D., Gimalac A., Van Duijn C., Gauvreau D., Ouellette G., Fortier I., Raelson J., Sherbatich T., Riazanskaia N., Rogaev E., Raeymaekers P., Aerssens J., Konings F., Luyten W., Macciardi F., Sham P.C., Straub R.E., Weinberger D.R., Cohen N., and Cohen D. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13675-13680
8. DeRosse P., Funke B., Burdick K.E., Lencz T., Ekholm J.M., Kane J.M., Kucherlapati R., and Malhotra A.K. Dysbindin genotype and negative symptoms in schizophrenia. Am. J. Psychiatry 163 (2006) 534-537
9. Detera-Wadleigh S.D., and McMahon F.J. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry 60 (2006) 106-114
10. Faraone S.V., Skol A.D., Tsuang D.W., Bingham S., Young K.A., Prabhudesai S., Haverstock S.L., Mena F., Menon A.S., Bisset D., Pepple J., Sautter F., Baldwin C., Weiss D., Collins J., Keith T., Boehnke M., Tsuang M.T., and Schellenberg G.D. Linkage of chromosome 13q32 to schizophrenia in a large Veterans affairs cooperative study sample. Am. J. Med. Genet. 114 (2002) 598-604
11. Harrison P.J., and Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361 (2003) 417-419
12. Hong C.J., Hou S.J., Yen F.C., Liou Y.J., and Tsai S.J. Family-based association study between G72/G30 genetic polymorphism and schizophrenia. NeuroReport 17 (2006) 1067-1069
13. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23 (1988) 99-110
14. Korostishevsky M., Kaganovich M., Cholostoy A., Ashkenazi M., Ratner Y., Dahary D., Bernstein J., Bening-Abu-Shach U., Ben-Asher E., Lancet D., Ritsner M., and Navon R. Is the G72/G30 locus associated with schizophrenia? Single nucleotide polymorphisms, haplotypes, and gene expression analysis. Biol. Psychiatry 56 (2004) 169-176
15. Lewis C.M., Levinson D.F., Wise L.H., DeLisi L.E., Straub R.E., Hovatta I., Williams N.M., Schwab S.G., Pulver A.E., Faraone S.V., Brzustowicz L.M., Kaufmann C.A., Garver D.L., Gurling H.M., Lindholm E., Coon H., Moises H.W., Byerley W., Shaw S.H., Mesen A., Sherrington R., O'Neill F.A., Walsh D., Kendler K.S., Ekelund J., Paunio T., Lonnqvist J., Peltonen L., O'Donovan M.C., Owen M.J., Wildenauer D.B., Maier W., Nestadt G., Blouin J.L., Antonarakis S.E., Mowry B.J., Silverman J.M., Crowe R.R., Cloninger C.R., Tsuang M.T., Malaspina D., Harkavy-Friedman J.M., Svrakic D.M., Bassett A.S., Holcomb J., Kalsi G., McQuillin A., Brynjolfson J., Sigmundsson T., Petursson H., Jazin E., Zoega T., and Helgason T. Genome scan meta-analysis of schizophrenia and bipolar disorder, Part II: schizophrenia. Am. J. Hum. Genet. 73 (2003) 34-48
16. Lewis D.A., and Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28 (2000) 325-334
17. Lin M.W., Sham P., Hwu H.G., Collier D., Murray R., and Powell J.F. Suggestive evidence for linkage of schizophrenia to markers on chromosome 13 in Caucasian but not Oriental populations. Hum. Genet. 99 (1997) 417-420
18. Lykouras L., Oulis P., Psarros K., Daskalopoulou E., Botsis A., Christodoulou G.N., and Stefanis C. Five-factor model of schizophrenic psychopathology: how valid is it?. Eur. Arch. Psychiatry Clin. Neurosci. 250 (2000) 93-100
19. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pikar D., and Breier A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17 (1997) 141-150
20. Meltzer D. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia. J. Clin. Psychiatry 60 Suppl. 3 (1999) 32-35
21. Mothet J.P., Parent A.T., Wolosker H., Brady Jr. R.O., Linden D.J., Ferris C.D., Rogawski M.A., and Snyder S.H. d-serine is an endogenous ligand for the lycine site of the N-methyl-d-aspartate receptor. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4926-4931
22. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10 (1962) 799-812
23. Owen M.J., O'Donovan M., and Gottesman I.I. Psychiatric Genetics and Genomics (2003), Oxford University Press, Oxford pp. 247-266
24. Rabinowitz D., and Laird N. A unified approach to adjusting association tests for population admixture with arbitrary pedigree structure and arbitrary missing marker information. Hum. Hered. 50 (2000) 211-223
25. Shaw S.H., Kelly M., Smith A.B., Shields G., Hopkins P.J., Loftus J., Laval S.H., Vita A., De Hert M., Cardon L.R., Crow T.J., Sherrington R., and DeLisi L.E. A genome-wide search for schizophrenia susceptibility genes. Am. J. Med. Genet. 81 (1998) 364-376
26. Shi Y.Y., and He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell. Res. 15 (2005) 97-98
27. Wang X., He G., Gu N., Yang J., Tang J., Chen Q., Liu X., Shen Y., Qian X., Lin W., Duan Y., Feng G., and He L. Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319 (2004) 1281-1286
28. Zou F., Li C., Duan S., Zheng Y., Gu N., Feng G., Xing Y., Shi J., and He L. A family-based study of the association between the G72/G30 genes and schizophrenia in the Chinese population. Schizophr. Res. 73 (2005) 257-261